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Abstract The inﬂuenza A virus RNA-dependent RNA polymer-
ase is a heterotrimer composed of PB1, PB2 and PA subunits
and essential for viral replication. However, little detailed struc-
tural information is available for this important enzyme. We
show by circular dichroism spectroscopy that polypeptides from
the C-terminus of PB1 that are capable of binding eﬃciently to
PB2 fold into stable a-helical structures. Structure prediction
analysis of this region of PB1 indicates that it likely consists
of a three-helical bundle. Deletion of any of the helices abrogated
transcriptional function. Thus, PB1 contains a C-terminal a-heli-
cal PB2-binding domain that is essential for nucleotide polymer-
ization activity.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Orthomyxovirus; Protein–protein; Drug design;
Polymerase
1. Introduction
Inﬂuenza A virus is a formidable pathogen that retains the
potential to cause global pandemics with mortality ﬁgures in
millions, despite a vaccination programme and the availability
of antiviral drugs [1]. Its genome consists of eight segments of
negative sense RNA separately encapsidated into ribonucleo-
protein (RNP) complexes with one copy of the viral RNA-
dependent RNA polymerase and stoichiometric amounts of
an RNA binding nucleoprotein, NP [2]. The RNA polymerase
is a heterotrimer of the PB1, PB2 and PA subunits that both
transcribes and replicates the viral genome. PB1 forms the
backbone of the polymerase complex and possesses nucleotide
polymerization activity [3,4]. PB2 primarily plays a role in
mRNA transcription initiation [3] whilst the precise function
of PA is uncertain (reviewed in [5]).
The polymerase complex is formed by a web of non-covalent
protein–protein interactions which have been examined in
some detail. Mapping experiments suggest a seemingly linear
arrangement of the polypeptide chains in which the C-terminus
of PA interacts with the N-terminus of PB1 while the C-termi-
nus of PB1 in turn binds to the N-terminus of PB2 [4,6–9].
However, electron microscope (EM) imaging of the polymer-
ase shows a compact, roughly globular structure [10–12] with
other regions of the polymerase subunits than those listed
above also contributing to trimer formation [13,14]. Muta-
tional analysis and trans-dominant inhibition experiments
indicate that the intermolecular contact regions of the poly-
merase are essential for enzymatic activity and are potentially
fruitful functions to target for the design of antiviral agents
[6,14–16]. Such experiments are worthwhile as existing inﬂu-
enza antiviral drugs suﬀer from problems of resistance and
low eﬃcacy and although viral polymerases often make good
antiviral targets, that of inﬂuenza virus remains under-
exploited [17]. Rational design of inﬂuenza polymerase inhibi-
tors is hindered by a lack of structural information on the
polypeptide complex. So far, there are low resolution EM
views of the polymerase trimer, in RNP form and as a free
complex [10–12], a high resolution structure of a domain com-
prised of the C-terminal 80 amino-acids from PB2 [18] and
partial proteolysis data suggesting that the N-terminal 212
amino-acids of PA represent a discrete domain [19]. Here, we
extend these data by showing that the C-terminal 75 amino-
acids of PB1 form an a-helical domain necessary for binding
PB2 and polymerase function.
2. Materials and methods
2.1. Plasmids and antisera
Plasmids encoding glutathione transferase (GST)-PB1 fusion pro-
teins pGEX1N683 and pGEX1N712, as well as pGEX16E6 are de-
scribed elsewhere [14]. Constructional details for other plasmids used
in this study are given in the supplementary information. Antisera di-
rected against PB1, PB2 and PA have been described previously [4,20].
All materials were derived from inﬂuenza virus A/PR/8/34.
2.2. Protein expression and binding assays
GST fusion proteins were expressed and puriﬁed by aﬃnity chroma-
tography on glutathione sepharose (GE Healthcare) as previously de-
scribed [14]. To obtain non-fused PB1 polypeptides, fractions eluted
from gluthathione sepharose columns were adjusted to contain
150 mM NaCl and 2.5 mM CaCl2, and incubated overnight with
10 U/mg of thrombin protease (Sigma) at room temperature. The di-
gested samples were fractionated by gel ﬁltration on Sephacryl S-200
(Pharmacia) equilibrated in 5 mM Tris–Cl, pH 7.6, 50 mM KCl. Frac-
Abbreviations: RNP, ribonucleoprotein; EM, electron microscope;
GST, glutathione-S-transferase; CAT, chloramphenicol acetyl trans-
ferase; WT, wild-type
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tions containing PB1 derived polypeptides were then passed over a
glutathione-sepharose column equilibrated in the same buﬀer to
remove residual GST protein before storage at 4 C. Protein concen-
trations were determined by the Bradford method [21] or by quantita-
tive amino-acid analysis.
Radiolabelled polymerase proteins were expressed in Xenopus oo-
cytes by microinjection of the appropriate in vitro transcribed mRNA
as previously described [4,14,20]. In vitro translation reactions in rab-
bit reticulocyte lysate were carried out as described [14]. ‘Pull down’
and co-immunoprecipitation binding assays were performed as previ-
ously described [4,14].
2.3. Circular dichroism spectroscopy
Measurements were recorded on an ISA Jobin Yvon CD6 instru-
ment ﬁtted with a thermostatically controlled cuvette holder and a
1 mm path length cuvette. Protein samples were in 5 mM Tris–Cl,
pH 7.6, 50 mM KCl. Wavelength scans were recorded from 195 to
250 nm in 0.5 nm increments, with a 1 s integration time, and were
averaged over ﬁve repetitions.
2.4. Virus infections and mammalian cell-based assays
293 T and CV1 cells were maintained as previously described [14,22].
Inﬂuenza virus RNPs were reconstituted by transfection of plasmids
expressing the three polymerase subunits, NP and a model virus gen-
ome segment encoding chloramphenicol acetyl transferase (CAT) as
previously described [22] or by infection of cells with recombinant vac-
cinia viruses expressing inﬂuenza virus RNP proteins and transfection
of in vitro transcribed CAT minigenome RNA [14]. RNA synthesized
by these RNPs was analysed by reverse-transcriptase primer extension
[22] and CAT polypeptide accumulation measured by ELISA [14].
3. Results
3.1. Delineation of C-terminal PB1 residues involved in
PB2-binding
Previous studies have shown that the C-terminus of PB1
contains a PB2 binding site but the precise location of the func-
tionally important sequences remains unclear. Initial studies
showed binding by relatively large fragments of the protein
containing >150 amino-acids and in one study, the ability of
PB1 fragments to act as trans-dominant inhibitors of viral gene
expression was further used to infer an interaction site lying
between amino acids 506 and 659 [6,8]. Contradicting this, a
subsequent study showed direct binding by the C-terminal 57
amino-acids (residues 700–757; [23]) and in agreement with
this we found that a GST fusion protein bearing the last 75
amino-acids of PB1 (G683) bound PB2 as eﬃciently as cognate
polyclonal antiserum [14]. Based on the behaviour of overlap-
ping C-terminal deletions, Ohtsu and colleagues suggested that
Fig. 1. PB1 C-terminal polypeptides. (A) Summary of constructs. PB1 C-terminal sequences are represented by black lines linked to GST or the rest
of the polypeptide as indicated. Predicted structural elements and their amino-acids coordinates are indicated by shaded (helices) or open (loops)
rectangles at the top. Qualitative summaries of the PB2-binding activity of the GST fusion proteins and the ability to support viral gene expression of
the non-fused PB1 polypeptides are given on the right. N.D.: not determined. (B) SDS–PAGE and Coomassie blue staining of the indicated GST
polypeptides. Thrombin digested polypeptides are denoted by/T, molecular mass standards (M, in kDa) are indicated on the left.
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amino-acids 718–732 were the most important for PB2-binding
[23]. However, a polypeptide containing amino-acids 715–740
showed only weak trans-dominant inhibitory activity against
the wild-type polymerase [15], perhaps indicating that addi-
tional sequences are required for eﬃcient binding.
Accordingly, to further examine the PB1 sequences neces-
sary for PB2-binding, we constructed a series of GST fusion
proteins containing between 12 and 91 residues from the C-ter-
minus of PB1 (Fig. 1A). The various fusion proteins as well as
non-fused GST were puriﬁed from Escherichia coli giving rise
to reasonably homogeneous preparations of polypeptides of
the expected sizes (Fig. 1B). However, on storage, the G667 fu-
sion protein containing amino-acids 667–757 of PB1 tended to
degrade (presumably from low level contamination with prote-
ase) to give rise to smaller protein species (Fig. 1B, lane 1).
Western blot analysis with an antiserum raised against the
C-terminus of PB1 conﬁrmed the expected reactivities of the
proteins (data not shown). Next, we tested the ability of the fu-
sion proteins to bind PB2 in pulldown assays. Radiolabelled
cell lysates containing either PB2 or PA were incubated with
the GST proteins to allow binding, before the addition of glu-
tathione sepharose. After collection and washing of the solid
phase, bound material was eluted and radiolabelled polypep-
tides detected by SDS–PAGE and autoradiography. As con-
trols, aliquots of the cell lysates were also directly
immunoprecipitated with anti-PB2 or -PA sera (Fig. 2A, lanes
2 and 9). Neither PB2 nor PA were precipitated from samples
incubated with GST (lanes 3 and 10) or PB2 by an irrelevant
GST fusion protein (Fig. 2B, lane 5). However, as before
[14] signiﬁcant quantities of PB2 were precipitated by a GST
fusion protein containing residues 683 onwards of PB1
(G683; Fig. 2A, lane 5). The interaction was speciﬁc because
there was no signiﬁcant precipitation of cellular polypeptides
(cf. lane 1) or PA (lane 12). Similarly, a fusion protein contain-
ing 91 residues from PB1 was also capable of binding PB2 but
not PA (G667; lanes 4 and 11), while one containing 46 amino-
acids interacted more weakly with PB2 (G712; Fig. 2A, lane 6;
B, lane 2). In addition, no precipitation of PB2 was observed if
the GST and PB1 sequences were ﬁrst separated by digestion
with the appropriate protease, or if thermally denatured PB2
was used (data not shown). The C-terminal 12 amino-acids
of PB1 were not suﬃcient to bind PB2 (Fig. 2A, lane 7) and
when these residues were removed from the larger fusion pro-
teins no major reduction in binding ability of the proteins was
apparent and in fact, deletion of the last 11 residues increased
the binding of a polypeptide beginning at residue 712 (Fig. 2B,
compare lanes 1 and 2 with 3 and 4, see Fig. 2C for quantiﬁ-
cation data). Therefore the C-terminal 75 amino-acids of
PB1 are capable of speciﬁcally and eﬃciently binding PB2,
and as little as 35 residues show good aﬃnity, while the last
11–12 residues apparently play little positive role (summarized
in Fig. 1A).
To test the role of the C-terminal PB2-binding sequences in
the context of otherwise full-length PB1, we examined the abil-
ity of C-terminally truncated PB1 mutants to form a complex
with PB2 and PA. The P proteins were expressed individually
or in combination in Xenopus oocytes and examined for asso-
ciation by co-immunoprecipitation [4,20]. When expressed
alone, PB2, PA, WT PB1 and the two C-terminally truncated
PB1 mutants were only precipitated in signiﬁcant amounts by
their cognate antisera (Fig. 3B and C). As before [4], when WT
PB1 was co-expressed with PB2 and PA, it was precipitated by
antisera to any of the three P proteins and conversely, PB2 and
PA were precipitated by anti-PB1 sera indicating formation of
the polymerase complex (Fig. 3A, lanes 1–3). Similar results
were obtained when a PB1 protein lacking the last 11 amino-
acids was tested (lanes 4–6). When a further truncated protein
ending at residue 731 was tested, it still co-precipitated with
PA (lanes 7 and 9). However, it showed a marked decrease
in eﬃciency of co-precipitation with PB2 (compare the
amounts of PB1 precipitated by anti-PB2 between lanes 2, 5
and 8). Thus consistent with the results obtained with GST-
PB1 fusions, the C-terminal 11 amino-acids of PB1 are dis-
pensable for PB2 binding, but further truncation reduces the
interaction.
3.2. Structural analysis of the PB1 C-terminus
Since PB2 was bound eﬃciently by a relatively small poly-
peptide from the C-terminus of PB1, it was of interest to deter-
mine whether this region possessed a discrete structure, and
could therefore be regarded as a true domain (i.e. folding inde-
pendently) of the polymerase. We accordingly digested the
G683 and G712 proteins with thrombin protease to separate
the GST and PB1 polypeptides (Fig. 1B, lanes 6 and 8), and
puriﬁed the PB1 fragments to near homogeneity (Fig. 1B, lanes
7 and 9). We then examined the structure of the polypeptides
Fig. 2. PB2-binding activity of GST fusion proteins. Aliquots of
radiolabelled (A) oocyte or (B) reticulocyte cell lysates containing PB2
or PA as labeled were examined by SDS–PAGE and autoradiography
before (Total) or after immunoprecipitation or pull down assays with
the indicated ligands. (C) Binding activity was quantiﬁed by densi-
tometry and the mean ± range of two independent assays plotted
relative to the amount of directly precipitated PB2 after subtraction of
background values.
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by circular dichroism (CD) spectroscopy. The spectra obtained
from PB1 683 and 712 at 4 C (Fig. 4A) displayed double min-
ima at 208 and 222 nm, which is characteristic of a-helical
structure [24]. From the values of the mean residue ellipticity
at 222 nm, we estimated total helical contents of 49% and
35% for 683 and 712 peptides, respectively [24]. To investigate
the stability of the polypeptides, we took spectra over a range
of temperatures and followed the thermal unfolding of the a-
helical structure by monitoring the mean residue ellipticity at
222 nm. The helical content of the 683 polypeptide remained
essentially constant at temperatures up to 20 C, but then fell
sharply between 30 and 60 C, with the midpoint of the unfold-
ing transition occurring at 42 C (Fig. 4B). The smaller C-ter-
minal fragment was less stable, as helical content decreased at
all temperatures above 4 C, with the midpoint of the unfold-
ing transition occurring at 34 C (Fig. 4B). CD spectra ob-
tained from the denatured polypeptides showed that virtually
all a-helical character had been lost at 80 C (Fig. 4A). Thus
the C-terminal 75 amino-acids of PB1 are capable of folding
into a discrete, partially a-helical structure in the absence of
the rest of the polypeptide.
To further investigate the structure of this C-terminal region
of PB1, we utilized bioinformatics. A secondary structure pre-
diction routine that used six separate prediction algorithms on
alignments of the C-termini of inﬂuenza A, B and C viruses to
produce a consensus output taking evolutionary information
into account (JPred; [25]) strongly predicted three a-helices
separated by loop regions (Fig. 5A). Structure predictions on
the more evolutionarily divergent Thogoto, Dhori and infec-
tious salmon anemia virus PB1 proteins also indicated three
helical regions (data not shown) suggesting this is a general
feature of orthomyxovirus PB1 proteins. Currently, there are
no solved structures with suﬃcient homology to the PB1 C-ter-
minus to permit a comparative modeling approach to predict a
tertiary structure. We therefore turned to an ab initio ap-
proach, using the 3Dpro program that uses secondary struc-
ture prediction coupled with a fragment library from the
Protein Data Bank and a simulated annealing model to ﬁnd
the lowest free energy structure [26]. The C-a backbone trace
was then further reﬁned and side-chain positions added using
the MaxSprout algorithm [27] and the Swiss pdb-viewer pro-
gram. This approach predicted essentially the same three heli-
Fig. 3. Ability of C-terminally truncated PB1 proteins to bind PB2 and
PA. The indicated PB1 polypeptides were expressed in oocytes (A) in
combination with PB2 and PA, (B) alone or (C) PB2 or PA were
expressed in isolation and the resulting cell lysates examined by SDS–
PAGE and autoradiography after immunoprecipitation with anti-PB1
(a-1), anti-PB2 (a-2) or anti-PA (a-A) sera. Note that PB2 and PA
were not resolved in lanes 4–6 of panel (i).
Fig. 4. Circular dichroism spectra of C-terminal PB1 polypeptides. (A) Spectra were recorded for PB1 683 (15 lM; squares) or 712 (19.9 lM; circles)
at 4 C (open symbols) or 80 C (ﬁlled symbols). (B) Unfolding of a-helices was monitored at increasing temperatures by monitoring mean residue
ellipticity at 222 nm. Values are plotted as the fraction of helix present at 4 C.
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ces as in Fig. 5A (albeit with a kink in helix 2) arranged anti-
parallel into a compact globular domain (Fig. 5B and C).
Thirty-ﬁve residues in total were predicted to be in a helical
conformation by the model, in good agreement with the spec-
troscopic results.
3.3. Functional analysis of the PB1 C-terminus
Next, we examined the role of the PB2-binding domain in
viral RNA synthesis. WT and mutant PB1 polypeptides lack-
ing the C-terminal 11 amino-acids (C746), a further truncation
removing predicted helix 3 (C738) or predicted helices 1 or 2
were tested for their ability to support viral gene expression
in a recombinant ‘mini-genome’ assay [14]. Transfection of a
plasmid encoding WT PB1 along with a synthetic vRNA con-
taining an antisense CAT gene in place of a viral ORF into
cells expressing PB2, PA and NP resulted in CAT polypeptide
expression (Fig. 6A, panel i). The PB1 C746 mutant also sup-
ported viral gene expression, albeit in slightly reduced amount
compared to WT PB1. However, further truncation to remove
helix 3 or separate deletion of either of helices 1 and 2 abol-
ished viral gene expression. None of the mutant PB1 polypep-
tides showed obvious signs of instability as Western blot
Fig. 5. Structural predictions for the C-terminus of PB1. (A) Secondary structures (coil, grey lines; a-helix, red bars) were predicted with the
indicated conﬁdence values (0, low; 9 high) for an alignment of the C-terminal regions of inﬂuenza A, B and C virus PB1 (amino-acid coordinates
refer to inﬂuenza A). Blue shading represents the degree of amino-acid conservation. (B, C) Tertiary structure prediction for the C-terminus of
inﬂuenza A virus PB1. Boundary residues of predicted helices and polypeptide N- and C-termini are indicated. The view in (C) is rotated 90
anticlockwise relative to (B).
Fig. 6. Function of C-terminally mutated PB1 molecules. (A) (i) Viral gene expression was assayed by measuring CAT polypeptide accumulation
after reconstitution of viral RNPs in CV1 cells with the indicated PB1 polypeptides. Prior titration experiments established that between 10 and
100 ng of the WT PB1 plasmid gave optimal gene expression (data not shown). (ii) PB1 accumulation was examined by Western blot analysis. (B)
Viral RNA synthesis from RNPs reconstituted in 293T cells with WT, mutant or without PB1 was examined by primer extension. Minigenome
RNAs were provided in cRNA (+CAT) or vRNA (CAT) sense.
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analysis showed similar accumulation levels to that of the WT
protein (Fig. 6A, panel ii). Thus mutations predicted to disrupt
the structure of the C-terminal domain and/or destroy PB2-
binding function inhibit viral gene expression.
The viral gene expression assay employed above measures
the ability of the polymerase to transcribe an input vRNA
molecule into mRNA without necessarily requiring genome
replication. To directly examine the role of the PB2-binding
domain in genome replication, we transfected cells with plas-
mids expressing either WT or a truncated form of PB1 lacking
the entire C-terminal domain (C682) along with PB2, PA, NP
and an inﬂuenza ‘mini genome’ RNA in either vRNA or
cRNA sense [22] and examined the accumulation of viral
RNA by primer extension. In cells containing WT RNP
proteins all three forms of viral RNA were synthesized whether
reactions were seeded with input cRNA or vRNA (Fig. 6B,
lanes 1 and 4, respectively), indicating that both genome
transcription and replication had occurred. However, in cells
containing the truncated PB1 protein, the only viral RNA
species detected were those that were also transcribed from
the transfected plasmid (lane 3, cRNA; lane 6, vRNA), simi-
larly to the background seen in the complete absence of PB1
(lanes 2 and 5). Thus a truncated form of PB1 lacking the
PB2-binding domain does not possess any signiﬁcant polymer-
ase activity.
4. Discussion
Here, we show that 35 amino-acids from the C-terminus of
PB1 comprising residues 712–746 are capable of eﬃciently
binding PB2 (Fig. 2). These results are in good agreement with
a previous study that inferred a core binding site between res-
idues 718–732 from the behaviour of small deletions within lar-
ger polypeptides [23]. However, our results suggest a binding
site extending slightly further towards the C-terminus and we
suspect this explains the relatively poor inhibitory activity
exhibited by a peptide including residues 715–740 noted in a
recent study [15]. Our results also strengthen the concept that
the PB1–PB2 interface is a valid target for antiviral interven-
tion as mutations within this region abolish transcriptional
activity of the polymerase (Fig. 6). The ﬁnding that loss of
the PB1 C-terminal domain inhibits genome replication
(Fig. 6B) despite allowing formation of a PB1-PA dimer
(Fig. 3) is consistent with previous studies showing that all
three polymerase subunits are necessary for nucleotide poly-
merization [28–31] but not with the hypothesis that PB1 and
PA suﬃce for replicative synthesis [32,33].
We also show that the C-terminal PB2-binding residues of
PB1 are likely contained within the context of an a-helical do-
main. The G683 fusion protein may provide a suitable con-
struct for future high resolution structural analysis. As well
as extending our knowledge of the domain structure of the
inﬂuenza A virus polymerase, these data may also prove useful
in the design of better inhibitors of the PB1–PB2 interaction.
There are interesting parallels with the herpes simplex virus
(HSV) DNA polymerase, where an essential interaction be-
tween the two subunits of the enzyme is mediated by an a-heli-
cal domain [34,35] that is susceptible to peptide inhibition
in vitro and in cells [36,37]. Furthermore, building on this
work, small-molecule inhibitors of the polypeptide interface
have been identiﬁed that possess antiviral activity [38]. Further
work is required to see if this strategy can be applied to the
inﬂuenza A virus polymerase.
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